Guizhou Taibang Biological Products, subsidiary of China Biologic Product, has collaborated with Xinjiang Deyuan Bioengineering to source raw plasma. The agreement allows Guizhou Taibang to source no less than 500 tonnes of source plasma from Xinjiang Deyuan over the next three years. The raw plasma will be shipped in batches to Guizhou Taibang for the production of human albumin and IVIG products. The company expects that the products made from the sourced raw plasma will begin to reach the market in second half of 2016.
Through the initial agreement, we laid a solid foundation for our further collaboration, gained trust from both our business partners and regulators, and demonstrated our strong operational capabilities, including quality control and production management."